| |
Figure 5. xYAP gain-of-function inhibits the expression of genes in the pre-placodal ectoderm, epidermis, premigratory neural crest, and hatching gland.(A) Genes expressed in the pre-placodal ectoderm (PPE), sox11 and six1, are dramatically reduced on the xYAP-injected sides (arrows). Brackets indicate the laterally located PPE expression domains on both sides the embryos. Anterior views. (B) Expression of the epidermis-specific cyto-keratin gene is lost on the xYAP-injected side. Anterior view. (C) The expression of genes characteristic of premigratory neural crest (foxD3, zic1 at bracket) are repressed on the xYAP-injected sides. Anterior-dorsal views. (D) pax3 expression in the surface ectodermal A-P stripe, which indicates the hatching gland progenitors (vertical arrows, HG) is repressed on the xYAP-injected side. In contrast, pax3 expression in the underlying neural crest progenitors is expanded (see Figure 6A). Dorsal view. (E) six1 expression in the otocyst (bracket) is reduced on the xYAP-injected side (right panel) compared to the uninjected side (Un) of the same embryo (left panel). Side views, stage 26. (F) The migratory path of foxD3-expressing neural crest cells (indicated by brackets) is truncated on the xYAP-injected side (right). Frontal view, stage 24. (G) neuroD expression in the trigeminal placode (bracket) is reduced on the xYAP-injected side (right panel) compared to the uninjected side (Un) of the same embryo (left panel). Side views, stage 22. |
